COX-1-derived thromboxane A2plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse

Blood

Volumn 124, Issue 10, 2014, Pages 1610-1621

  Yang, Qiong ^a   Shi, Maohua ^a   Shen, Yujun ^b   Cao, Yingjiao ^a   Zuo, Shengkai ^b   Zuo, Caojian ^b   Zhang, Hui ^a,c   Gabrilovich, Dmitry I ^d   Yu, Ying ^b   Zhou, Jie ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLSALICYLIC ACID; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1; INTERLEUKIN 7; JANUS KINASE; STAT5 PROTEIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; TRANSCRIPTION FACTOR PAX5; MEMBRANE PROTEIN; PTGS1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW; BONE MARROW CELL; CELL COUNT; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; GENETICS; KNOCKOUT MOUSE; LEUKOPOIESIS; METABOLISM; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLOOXYGENASE 1; HUMANS; JANUS KINASES; LEUKOPOIESIS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; THROMBOXANE A2;

EID: 84907053121     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559658     Document Type: Article

References (46)

1. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79.
2. Ramírez J, Lukin K, Hagman J. From hematopoietic progenitors to B cells: mechanisms of lineage restriction and commitment. Curr Opin Immunol. 2010;22(2):177-184.
3. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6):715-725.
4. Mandel EM, Grosschedl R. Transcription control of early B cell differentiation. Curr Opin Immunol. 2010;22(2):161-167.
5. Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Farrar MA. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol. 2004;172(8):4770-4778.
6. Kikuchi K, Lai AY, Hsu CL, Kondo M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med. 2005;201(8):1197-1203.
7. Sudo T, Nishikawa S, Ohno N, et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci USA. 1993;90(19):9125-9129.
8. Dias S, Silva H Jr, Cumano A, Vieira P. Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. J Exp Med. 2005;201(6):971-979.
9. Akerblad P, Sigvardsson M. Early B cell factor is an activator of the B lymphoid kinase promoter in early B cell development. J Immunol. 1999;163(10):5453-5461.
10. Maier H, Hagman J. Roles of EBF and Pax-5 in B lineage commitment and development. Semin Immunol. 2002;14(6):415-422.
11. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8(5):463-470.
12. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182.
13. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063-1073.
14. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004;36(7):1187-1205.
15. Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog Lipid Res. 2003;42(5):377-404.
16. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15-19.
17. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(5):413-421.
18. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.
19. Yu Y, Cheng Y, Fan J, et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest. 2005;115(4):986-995.
20. Lu L, Osmond DG. Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow. Immunol Rev. 2000;175:158-174.
21. Sharabi AB, Aldrich M, Sosic D, et al. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008;6(12):e316.
22. Šošič D, Richardson JA, Yu K, Ornitz DM, Olson EN. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell. 2003;112(2):169-180.
23. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999;5(6):1569-1582.
24. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193-1226.
25. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118(1):18-35.
26. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270(49):29051-29054.
27. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem. 1991;266(14):9309-9313.
28. Kozasa T, Jiang X, Hart MJ, et al. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science. 1998;280(5372):2109-2111.
29. Leaberry BA. Aspirin for the prevention of cardiovascular disease: systematic review. J Nurs Care Qual. 2010;25(1):17-21.
30. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188(1):21-28.
31. Li H, Edin ML, Gruzdev A, et al. Regulation of T helper cell subsets by cyclooxygenases and their metabolites. Prostaglandins Other Lipid Mediat. 2013;104-105:74-83.
32. Chen EP, Smyth EM. COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat. 2011;96(1-4):14-20.
33. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664-2674.
34. Blaho VA, Buczynski MW, Dennis EA, Brown CR. Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17. J Immunol. 2009;183(9):5644-5653.
35. Choi SH, Aid S, Choi U, Bosetti F. Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J. 2010;10(5):448-457.
36. Yang CW, Unanue ER. Neutrophils control the magnitude and spread of the immune response in a thromboxane A2-mediated process. J Exp Med. 2013;210(2):375-387.
37. Kabashima K, Murata T, Tanaka H, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol. 2003;4(7):694-701.
38. Remuzzi G, Noris M, Benigni A, Imberti O, Sayegh MH, Perico N. Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. J Exp Med. 1994;180(5):1967-1972.
39. Stachowska E, Dolegowska B, Dziedziejko V, et al. Prostaglandin E2 (PGE2) and thromboxane A2 (TXA2) synthesis is regulated by conjugated linoleic acids (CLA) in human macrophages. J Physiol Pharmacol. 2009;60(1):77-85.
40. Kolenko V, Rayman P, Roy B, et al. Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood. 1999;93(7):2308-2318.
41. Rodriguez G, Ross JA, Nagy ZS, Kirken RA. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. J Biol Chem. 2013;288(10):7137-7146.
42. Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Aspirin and immune system. Int Immunopharmacol. 2012;12(1):10-20.
43. Kondo N, Takao A, Orii T. Case report: immunoglobulin A deficiency in patients with juvenile rheumatoid arthritis treated with aspirin. Biotherapy. 1993;7(1):59-62.
44. Grotz W, Siebig S, Olschewski M, Strey CW, Peter K. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation. 2004;77(12):1848-1853.
45. Zailaie MZ. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. Saudi Med J. 2005;26(7):1085-1091.
46. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009;258(1):18-28.